Related Experiment Video
Updated: Aug 29, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Analysis of polymorphic patterns in candidate genes in Israeli patients with prostate cancer
Arie Figer1, Tal Friedman, Ayse Esra Manguoglu
1Institute of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Background:
The precise genes involved in conferring prostate cancer risk in sporadic and familial cases are not fully known.
Objectives:
To evaluate the genetic profile within several candidate genes of unselected prostate cancer cases and to correlate this profile with disease parameters.
Methods:
Jewish Israeli prostate cancer patients (n = 224) were genotyped for polymorphisms within candidate genes: p53, ER, VDR, GSTT1, CYP1A1, GSTP1, GSTM1, EPHX and HPC2/ELAC2, followed by analysis of the genotype with relevant clinical and pathologic parameters.
Results:
The EPHX gene His113 allele was detected in 21.4% (33/154) of patients in whom disease was diagnosed above 61 years, compared with 5.7% (4/70) in earlier onset disease (P < 0.001). Within the group of late-onset disease, the same allele was noted in 5.5% (2/36) with grade I tumors compared with 18% (34/188) with grade II and up (P = 0.004). All other tested polymorphisms were not associated with a distinct clinical or pathologic feature in a statistically significant manner.
Conclusions:
In Israeli prostate cancer patients, the EPHX His113 allele is seemingly associated with a more advanced, late-onset disease. These preliminary data need to be confirmed by a larger and more ethnically diverse study.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase